UK – NICE u-turn backs Stelara for UC

The National Institute for Health and Care Excellence (NICE) has now issued a positive Final Appraisal Document (FAD) recommending Janssen's Stelara (ustekinumab) as an option for treating ulcerative colitis, having initially rejected the drug earlier this year.

Specifically, NHS funding is being approved for the drug’s use to treat moderately to severely active ulcerative colitis (UC) in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if: a tumour necrosis factor (TNF)-alpha inhibitor has failed, cannot be tolerated, or is unsuitable.

Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines, known to play a key role in inflammatory and immune responses, offering a new mechanism of action for treating the condition…